| 1 |
34803097 | The 30-year Natural History of Non-classic Fabry Disease with an R112H Mutation. | 2021 Nov 20 |
2 |
| 2 |
32127409 | Accumulation of Globotriaosylceramide in Podocytes in Fabry Nephropathy Is Associated with Progressive Podocyte Loss. | 2020 Apr |
1 |
| 3 |
32868283 | Assessing the role of glycosphingolipids in the phenotype severity of Fabry disease mouse model. | 2020 Nov |
1 |
| 4 |
30013462 | Altered Gene Expression in Prefrontal Cortex of a Fabry Disease Mouse Model. | 2018 |
4 |
| 5 |
30054149 | Non-clinical evaluation of JR-051 as a biosimilar to agalsidase beta for the treatment of Fabry disease. | 2018 Sep |
2 |
| 6 |
30328411 | Characterization of small fiber pathology in a mouse model of Fabry disease. | 2018 Oct 17 |
3 |
| 7 |
27756537 | Differences in cleavage of globotriaosylceramide and its derivatives accumulated in organs of young Fabry mice following enzyme replacement therapy. | 2017 Jan - Feb |
2 |
| 8 |
28161408 | Anti-BlyS antibody reduces the immune reaction against enzyme and enhances the efficacy of enzyme replacement therapy in Fabry disease model mice. | 2017 May |
1 |
| 9 |
28601129 | Fabry disease: diagnostic methods in nephrology practice. | 2017 Supplement 1 |
2 |
| 10 |
28649509 | Fabry disease: Four case reports of meningioma and a review of the literature on other malignancies. | 2017 Jun |
2 |
| 11 |
28662189 | Affective and cognitive behavior in the alpha-galactosidase A deficient mouse model of Fabry disease. | 2017 |
2 |
| 12 |
28756410 | Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment. | 2017 Nov |
1 |
| 13 |
27145802 | Comprehensive and differential long-term characterization of the alpha-galactosidase A deficient mouse model of Fabry disease focusing on the sensory system and pain development. | 2016 |
1 |
| 14 |
27531673 | Increased expression of Trpv1 in peripheral terminals mediates thermal nociception in Fabry disease mouse model. | 2016 |
1 |
| 15 |
24232002 | Endothelial nitric oxide synthase uncoupling and microvascular dysfunction in the mesentery of mice deficient in α-galactosidase A. | 2014 Jan |
4 |
| 16 |
25337704 | Pain related channels are differentially expressed in neuronal and non-neuronal cells of glabrous skin of fabry knockout male mice. | 2014 |
1 |
| 17 |
22425450 | Enzyme replacement therapy partially prevents invariant Natural Killer T cell deficiency in the Fabry disease mouse model. | 2012 May |
2 |
| 18 |
23007467 | Possible role of transforming growth factor-β1 and vascular endothelial growth factor in Fabry disease nephropathy. | 2012 Dec |
4 |
| 19 |
23766930 | Glycosphingolipid Mediated Caveolin-1 Oligomerization. | 2012 Feb 18 |
1 |
| 20 |
20846825 | Promoter-specific lentivectors for long-term, cardiac-directed therapy of Fabry disease. | 2011 Jan |
4 |
| 21 |
20961863 | Increased globotriaosylceramide levels in a transgenic mouse expressing human alpha1,4-galactosyltransferase and a mouse model for treating Fabry disease. | 2011 Feb |
3 |
| 22 |
21047542 | Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease. | 2011 Feb 10 |
4 |
| 23 |
21328014 | Kidney histologic alterations in α-Galactosidase-deficient mice. | 2011 Apr |
1 |
| 24 |
21477968 | Myocardial alterations in the murine model of fabry disease can be reversed by enzyme replacement therapy. | 2011 May-Jun |
1 |
| 25 |
19639234 | Expression of genes and their responses to enzyme replacement therapy in a Fabry disease mouse model. | 2009 Sep |
2 |
| 26 |
18219591 | Naked plasmid DNA-based alpha-galactosidase A gene transfer partially reduces systemic accumulation of globotriaosylceramide in Fabry mice. | 2008 Feb |
5 |
| 27 |
18565198 | Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect. | 2008 Oct |
2 |
| 28 |
17535804 | Caveolin-associated accumulation of globotriaosylceramide in the vascular endothelium of alpha-galactosidase A null mice. | 2007 Jul 20 |
1 |
| 29 |
17697536 | Enzyme replacement therapy in patients with Fabry's disease. | 2007 Jul-Aug |
2 |
| 30 |
14716680 | Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors. | 2004 Jan |
1 |
| 31 |
12538729 | Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis. | 2003 Feb |
1 |
| 32 |
12624185 | Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer. | 2003 Mar 18 |
4 |
| 33 |
12027559 | Adenovirus-transduced lung as a portal for delivering alpha-galactosidase A into systemic circulation for Fabry disease. | 2002 Jun |
1 |
| 34 |
10840053 | Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. | 2000 Jun 20 |
4 |
| 35 |
10841515 | Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. | 2000 Jun |
2 |